FDA Warned Amazon Over Unapproved Herpes Treatments
Online retailers must ensure health product listings meet strict regulatory approval standards to avoid enforcement actions.
Updated on Oct. 7, 2026 in Healthcare
Live Poll
Do you trust online retailers to ensure health products sold on their platforms are safe?
The FDA issued a warning letter to Amazon on October 1, 2026, after investigators purchased several unapproved herpes treatments from the platform in July 2026. The agency classified the products as unapproved new drugs, noting that no over-the-counter treatments for sexually transmitted infections have received FDA approval.
Why it matters
The agency cited public health concerns, stating that these unapproved products may lead consumers to forgo necessary medical care. This enforcement action highlights increasing federal scrutiny of third-party retail platforms that facilitate the sale of unauthorized health and wellness products.
The FDA identified nine specific products as unapproved new drugs, ranging from ointments to intimate washes, and established a firm 15-business-day deadline for Amazon to provide a written response.
The players
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
Amazon
A global e-commerce and technology company that operates a massive third-party retail marketplace subject to federal regulatory oversight.
The details
The FDA conducted a review of ingredient lists to determine if these items met federal definitions for homeopathic drugs. By selling these products, Amazon faces regulatory pressure to tighten oversight of its third-party marketplace to ensure that health-related listings comply with drug approval requirements. The agency previously issued similar warnings to the company in 2023 regarding energy supplements and in 2024 concerning chemical peel products.
Timeline
July 2026: FDA investigators purchased herpes products from Amazon to evaluate compliance.
October 1, 2026: The FDA issued a formal warning letter to Amazon regarding the identified products.
Within 15 business days of October 1, 2026: Amazon must submit a formal written response to the FDA.
Market Landscape
This warning aligns with the FDA's enforcement of the Federal Food, Drug, and Cosmetic Act regarding unapproved new drugs. It marks a continued effort by regulators to place accountability for medical product compliance onto major retail platforms.
Business owners selling health or wellness products online should audit their listings to ensure they do not claim to treat conditions without specific FDA approval. Compliance officers should monitor FDA warning letters to identify product categories currently under increased federal surveillance.
The takeaway
The FDA consistently targets retailers for facilitating the sale of unapproved medical items as a means of managing broader public health risks. Operators should review their product catalogs against FDA advisory lists to ensure they are not inadvertently selling prohibited supplements or treatments.
What happens next
Amazon is required to provide a written response detailing its plan to address these violations within 15 business days of the October 1, 2026, letter.
Further reading
For more on industry regulatory standards, visit the Healthcare section.
Live Poll
Do you trust online retailers to ensure health products sold on their platforms are safe?
